Among these, drugs against CAIX have been used in preclinical in vivo models revealing a great potential in inhibiting the formation of metastases in several types of cancer [153, 154] and have been also used in cancer patients [155], like for the CAIX inhibitor SLC-0111 (ClinicalTrials.gov Identifier: NCT02215850 Phase I, NCT03450018 Phase Ib). The gene discussed is CA9; the disease is cancer.